TRIAL DETAIL

A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors

Drug:
Trial Name:
A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors
NCT#:
Conditions:
Solid Tumors
Status:
Completed
Phase:
1
Start Date 06/01/2009
Age of Trial (yrs) 13.1
Treatment Phase:
Gleevec-resistant
Drug Category:
HSP90 inhibitor
Strategy:
Destroy KIT
Trial Type:
GIST not specified. GIST patient enrollment unknown.
Other Protocol IDs:
CHSP990A2101, EUDRACT number 2008-006440-19
Sponsor:
Novartis
Patient Contact:
Novartis Pharmaceuticals +1-800-340-6843
Contact email:
Contact Phone:
+1-800-340-6843
Randomized:
IV or Oral:
Oral
Trial Notes:
This study will study the safety, tolerability and metabolism of a drug called HSP990 when given by mouth once a week to subjects with advanced solid tumors.

Prior treatment with any Hsp90 or HDAC inhibitor compound is an exclusion factor.

Trial Links

Trial Results

Drug Information

Novartis pipeline page
 
Vernalis pipeline page
 

Trial Sites

Name
Address
City
State
Zip
Country
Augusta
GA
30912
USA
3322 West End Avenue
Nashville
TN
37203
USA
Toulouse
31052
France
Toronto
ON
Canada
Barcelona
08035
Spain